TITLE
Anti-IL-17 monclonal antibody ixekizumab effect on chronic psoriasis

SUMMARY
Analysis of psoriatic skin biopsies from patients treated with 150mg of subcutaneous anti-IL-17 mAb ixekizumab (previously LY2439821) at weeks 0 and 2. IL-17 blockade resulted in a high-grade clinical improvement in psoriasis. Results provide insight into the role of IL-17 in disease pathogenesis.

ORGANISM
Homo sapiens

PLATFORM
GPL571 : [HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array

CITATIONS
Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012 Jul;130(1):145-54.e9. PMID:  22677045

